A Multicentre Retrospective Study of Characterization of Treatment Intensified (Add on to Metformin) Real World Adult Population With Type 2 Diabetes Mellitus in India, Pakistan, and Thailand.

Registration

Registration

NCT05542420

Acronym

CONVERGE

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

3000

Start

2022-10-19

Primary completion

2023-04-20

Lead sponsor

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2

Interventions

OTHER:No treatment given

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U1111-1273-4446

Registered primary outcomes

• BMI (body mass index) [6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective)]
• Most recent blood pressure measurement values [6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective)]
• The proportion of patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA) [At Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class)]
• The proportion of patients prescribed cardiovascular disease (CVD) medications [Since the start of medical record]